• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Revlon

Revlon

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. MediaTek Releases the MT6753: A WorldMode 64-bit Octa-Core Smartphone SoC

    MediaTek Releases the MT6753: A WorldMode 64-bit Octa-Core Smartphone SoC

  2. Fitch Affirms Irvine Ranch Water District, CA COPs, Rev Bonds, and Notes at 'AAA'; Outlook Stable

    Fitch Affirms Irvine Ranch Water District, CA COPs, Rev Bonds, and Notes at 'AAA'; Outlook Stable

  3. Fitch Rates Sacramento County Sanitation Dist Fin Auth, CA Rev Bonds 'AA'; Outlook Stable

    Fitch Rates Sacramento County Sanitation Dist Fin Auth, CA Rev Bonds 'AA'; Outlook Stable

  4. Fitch Affirms L.A. Arena Funding (Staples Center) Arena Rev -backed Notes at 'BBB+'; Outlook Stable

    Fitch Affirms L.A. Arena Funding (Staples Center) Arena Rev -backed Notes at 'BBB+'; Outlook Stable

  5. AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

    AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

  6. Fitch Upgrades Cedars Sinai Medical Center (CA) Rev Bonds to 'AA-'; Outlook Revised to Stable

    Fitch Upgrades Cedars Sinai Medical Center (CA) Rev Bonds to 'AA-'; Outlook Revised to Stable

  7. Fitch Rates Butler Health System (PA) Series 2015A Rev Bonds 'A-'; Outlook Stable

    Fitch Rates Butler Health System (PA) Series 2015A Rev Bonds 'A-'; Outlook Stable

  8. UPDATE: Mr. Market is about to take your money on a wild ride

    UPDATE: Mr. Market is about to take your money on a wild ride

  9. Fitch Affirms University of Chicago (IL) Revs at 'AA+'; Outlook Stable

    Fitch Affirms University of Chicago (IL) Revs at 'AA+'; Outlook Stable

  10. AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan

    AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.